+86-28-82633987
Product name: Eriocalyxin B
Synonym name:
Catalogue No.: SBP00090
Cas No.: 84745-95-9
Formula: C20H24O5
Mol Weight: 344.407
Botanical Source:
Type of Compound:
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
HPLC of Eriocalyxin B
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
83.8300
1.2962
1.2961
.0985
2.4086
11.2695
High
65.8696
6.8384
No
No
No
No
Yes
No
0.0
Yes
Yes
Yes
Yes
Eriocalyxin B (CAS No.: 84745-95-9) is a diterpene natural product isolated from the traditional Chinese medicinal herb Isodon eriocalyx. As a natural compound with multiple biological activities, Calyx ethylene demonstrates broad research value in anti-tumor, anti-inflammatory, and metabolic regulation fields. In recent years, with deeper analysis of its molecular mechanisms, Calyx acetin has become one of the hot topics in natural product pharmacology research due to its ability to induce tumor cell apoptosis and autophagy, as well as to regulate various signaling pathways. This paper will systematically review the chemical structure and physicochemical properties of Calyx acetin, plant origin and extraction methods, pharmacological activity, mechanism of action and molecular targets, druggability evaluation, and pharmacokinetic characteristics, and explore its clinical application prospects and future development directions.
Calyx acetosin belongs to the diterpene class of compounds, with the molecular formula C20H24O5 and a molecular weight of 344.4070. Its structural features include a typical tetracyclic framework and multiple oxidized functional groups, giving it high biological activity. The LogP value of Calyx ethylene is 1.2962, indicating moderate lipid solubility, which facilitates cell membrane penetration. The polarized surface area (TPSA) was 83.83 Ų, indicating a good balance between membrane permeability and targeted binding. It has relatively low water solubility (0.0985 mg/mL), which may affect its bioavailability. Notably, Mao Calyx ethylene has a high blood-brain barrier penetration ability, suggesting its potential application value in central nervous system diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenic test result was 0.0, indicating a low genotoxicity risk and meeting safety requirements.
Isodon eriocalyx is mainly derived from the Lamiaceae plant Isodon eriocalyx, which is widely used in traditional Chinese medicine for anti-inflammatory, anti-tumor, and immunomodulatory purposes. Maoye Fragrant Tea Vegetable is distributed in many southern provinces of China, with Yunnan and Sichuan as the main production areas.
The extraction of calyx ethylene usually uses solvent extraction combined with chromatography separation technology. Common extraction solvents include ethanol, methanol, and ethyl acetate. The typical extraction process is: crush the dried plant plants or stems and leaves, extract with organic solvents, concentrate the extract, and purify it by silica gel column chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), and other methods. In recent years, the application of new technologies such as ultrasound-assisted extraction and microwave-assisted extraction has improved the extraction efficiency and purity of calyx ethylene. In addition, structural identification of calyx ethylene mainly relies on modern analytical methods such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared spectroscopy (IR).
Maocalyxin exhibits significant inhibitory effects in various tumor cell lines, including breast cancer, lung cancer, liver cancer, colorectal cancer, and leukemia. In vitro experiments show that Calyx acetin can significantly reduce the proliferation capacity of tumor cells, induce cell cycle arrest, and promote apoptosis and autophagy. Animal model studies have also confirmed its antitumor effects, manifested by reduced tumor size and longer survival.
Calyx ethylene exerts anti-inflammatory activity by regulating the expression of various inflammatory mediators. It can inhibit the secretion of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, thereby reducing inflammatory responses. Related studies show that Maocalyx ethylene exerts anti-inflammatory effects by inhibiting the NF-κB and MAPK signaling pathways, thereby reducing the transcription activity of inflammatory genes.
Research on the regulation of fat metabolism by Mao Calyx acetin is relatively novel. It can inhibit adipocyte differentiation and lipid accumulation, reduce the expression of genes related to fat formation, suggesting its potential application value in the prevention and treatment of diseases such as obesity and metabolic syndrome.
In addition, Calyx ethylene also exhibits certain immunomodulatory effects, able to regulate T cell function and improve the pathological state of autoimmune diseases. Its protective effects on the nervous system and antioxidant activity have also gradually attracted attention.
The multi-target mechanism of Calyx ethylene is the foundation of its various pharmacological activities. The main targets and signaling pathways involved are as follows:
MCL1 and BCL2: As anti-apoptotic proteins, the downregulation of MCL1 and BCL2 is an important mechanism by which Calyx acetosin induces tumor cell apoptosis. Calyx acetosin disrupts the anti-apoptotic balance within cells by regulating the expression of these proteins, thereby promoting apoptosis.
STAT3: Signal transduction and transcription activator factor 3 (STAT3) is a key regulatory factor for tumor cell proliferation and immune evasion. Calyx acetin can inhibit STAT3 phosphorylation and nuclear translocation, block its transcriptional activity, and suppress tumor cell growth and survival.
MMP2: Matrix metalloproteinase 2 (MMP2) is involved in tumor cell invasion and metastasis. Calyx acetogen reduces tumor cell migration and invasion ability by inhibiting the expression and activity of MMP2.
TOP1 and TOP2A :D NA topoisomerases I and IIα (TOP1, TOP2A) are key enzymes in DNA replication and transcription. Calyx ethylene inhibits the activity of these two enzymes, interferes with the DNA metabolism of tumor cells, and induces cell death.
HIF1A: Hypoxia-inducing factor 1α (HIF1A) promotes angiogenesis and metabolic reprogramming in the hypoxic environment of tumors. Calyx acetin blocks the tumor's adaptive response by inhibiting HIF1A expression.
MAPK1: The MAPK signaling pathway regulated by calyx ethylene is involved in cell proliferation, differentiation, and stress responses, with inhibitory effects that help with anti-inflammatory and antitumor effects.
ESR1 and CYP19A1: Estrogen receptor α (ESR1) and aromatase (CYP19A1) are important targets in hormone-dependent tumors such as breast cancer. The regulation of both by Maocalyxin suggests its potential in the treatment of hormone-related tumors.
Overall, Mao Calyx acetosin achieves multiple biological effects of anti-tumor, anti-inflammatory, and metabolic regulation through multi-target and multi-pathway synergistic effects.
The druggability parameters of Mao Calyx acetin indicate that it has good potential for drug development. Moderate molecular weight and moderate LogP values facilitate drug distribution in vivo and cell membrane penetration. A higher polarized surface area (TPSA) helps it bind to target proteins. Although water solubility is relatively low, bioavailability can be improved through pharmaceutical formulation technologies such as nanocarriers and solid dispersions.
The high penetration of the blood-brain barrier opens up possibilities for its application in neurological diseases. The non-inhibitory nature of the hERG channel reduces the risk of cardiotoxicity, and a negative Ames test suggests a lower genotoxicity risk and better safety.
Currently, pharmacokinetic research on Calyx acetin is relatively limited, but preliminary data indicate it has good stability and distribution characteristics in vivo. In the future, further systematic research on in vivo metabolic pathways, half-life, bioavailability, and excretion mechanisms is needed to guide preclinical and clinical development.
The potential of Calyx acetosin in the field of antitumor therapy is particularly prominent. Its multi-target mechanism enables it to overcome resistance issues with single-target drugs, making it suitable for development as combination or multi-target anticancer drugs. Especially in the fields of breast cancer, lung cancer, and hematologic tumors, Mao Cao Yi Su shows promising therapeutic prospects.
In addition, the anti-inflammatory and immunomodulatory effects of Mao Calyx ethylene provide new ideas for the treatment of autoimmune diseases. Its inhibition of fat production also suggests its potential application in metabolic diseases such as obesity and fatty liver.
Future research should focus on the following areas:
Pharmacokinetics and Safety Evaluation: Systematic in vivo metabolism, toxicology, and safety studies lay the foundation for clinical trials.
Formulation Development: Optimizing administration routes and formulation forms to improve the bioavailability and targeting of Calyx Ethylene.
Mechanism research: In-depth analysis of its multi-target action network, exploring new targets and signaling pathways.
Clinical Research: Conduct early-stage clinical trials to evaluate treatment efficacy and safety.
Combination therapy strategy: Explore synergistic effects with existing anticancer drugs and immunomodulators to enhance treatment outcomes.
As a natural diterpene product with multiple biological activities, Calyx acetin shows broad application prospects in anti-tumor, anti-inflammatory, and metabolic regulation fields due to its unique chemical structure and multi-target mechanism. Although still in the preclinical research stage, its favorable druggability parameters and safety profile provide a solid foundation for future drug development. With the ongoing advancement of pharmacokinetics, mechanistic research, and clinical evaluation, Mao Cao ethylene is expected to become an important candidate molecule in natural product drug development, bringing new breakthroughs in the treatment of tumors and related diseases.
Shenshuai
Wenjing
Hedandan
